Laboratory Testing and the Thrombophilia WorkupSurgeon General's Workshop on Deep Vein Thrombosis1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 Return to Menu
SLIDE 1: Laboratory Testing and the Thrombophilia Workup Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 8 May 2006 Return to Top SLIDE 2: Roles of the Clinical Laboratory - Useful ancillary data for initial diagnosis (d-dimer).
- Monitoring antithrombotic therapy.
- Evaluation for underlying hypercoagulable state(s).
- Identifies individuals 'at risk' for thrombosis.
- Identifies individuals with an initial thrombosis who are at higher risk for recurrence.
Return to Top SLIDE 3: What laboratory tests are useful in the acute setting? - D-dimer (right arrow) supportive data to help rule out venous thromboembolism.
- Troponins/BNP (right arrow) stratify severity of PE.
- PT, aPTT (right arrow) essential baseline information prior to starting therapy.
- Hypercoagulable workup generally not useful in the acute setting.
Return to Top SLIDE 4: Who should be considered for thrombophilia testing? - Patients with unexplained, or 'idiopathic' thromboembolism.
- Patients with thromboembolism that is unusually extensive, or in an unusual location (e.g., portal vein thrombosis).
- Patients with a striking family history for venous thromboembolism.
Return to Top SLIDE 5: What tests should be done? - Activated protein C resistance, with analysis for factor V Leiden if positive.
- Prothrombin G20210A genotype analysis.
- Antithrombin functional assay.
| - Protein C functional assay.
- Protein S functional assay, with antigenic assays if indicated.
- Antiphospholipid antibody testing.
- Homocysteine level.
- Factor VIII assay.
|
Return to Top SLIDE 6: Thrombophilic states and race 2 pie charts, 1 for Caucasian and 1 for African-American. Caucasian FVL | 14.5 | PT G20210A | 8.2 | AT deficiency | 1.9 | PC deficiency | 3.7 | PS deficiency | 2.3 | Elevated FVIII | 25 | APLA | 10 | | 34.4 |
African-American FVL | 14.5 | PT G20210A | 8.2 | AT deficiency | 1.9 | PC deficiency | 3.7 | PS deficiency | 2.3 | Elevated FVIII | 25 | APLA | 10 | | 34.4 |
Return to Top SLIDE 7: Thrombophilia in the pediatric patient - Many studies include children with central venous lines and other acquired disorders.
- Elevated factor VIII and D-dimer is also associated with recurrent thrombosis
Pie chart. Age: neonate to 18 yrs Combined defects FVL | 29.2 | PT G20210A | 3.7 | AT deficiency | 1.7 | PC deficiency | 6.6 | PS deficiency | 1.3 | Elevated Lp(a) | 14.9 | Combined defects | 20.9 | | 21.7 |
Return to Top SLIDE 8: Impact of thrombophilic disorders on recurrent thromboembolism Line chart showing Impact of thrombophilic disorders on recurrent thromboembolism Return to Top SLIDE 9: ACCP Guidelines 2.1.4. For patients with first episode DVT and: - Antiphospholipid antibodies;
- 2 or more thrombophilic conditions;
- (right arrow) therapy for 12 months (1C+) or indefinite (2C).
2.1.5. For patients with first episode DVT and: - Antithrombin, protein C or protein S deficiency;
- Factor V Leiden or prothrombin G20210A;
- Elevated homocysteine or factor VIII levels
- (right arrow) therapy for 6-12 months (1A) or indefinite (2C).
Return to Top SLIDE 10: Cost of thrombophilia testing Test | Approximate Cost* |
---|
Natural anticoagulants (antithrombin, protein C, protein S): | $450-750 | Genetic tests (factor V Leiden, prothrombin G20210A): | $600 | Antiphospholipid antibodies: | $1000-1500 | Other (factor VIII, homocysteine): | $200 | TOTAL: | $2250-3050 |
* Duke Coagulation Laboratory Return to Top SLIDE 11: What should healthcare providers do with this information? - Individuals who test positive for a thrombophilic risk factor require counseling as to:
- risks of thrombosis to themselves and their family members.
- importance of early recognition of signs and symptoms of venous thromboembolism.
- risks and benefits of thromboprophylaxis in high-risk situations.
Return to Top SLIDE 12: Should asymptomatic individuals be screened for thrombophilia? - Screening of asymptomatic individuals, whether family members of a patient with thrombosis, or in a situation that places them at increased risk for thrombosis, is generally not recommended.
- However, in selected situations, knowledge of a specific thrombophilic state might guide therapeutic decision-making (e.g., decision concerning HRT usage).
Return to Top SLIDE 13: On the other hand, one doesn't even need the doctor to order the test... Photo of www.dnadirect.com Return to Top SLIDE 14: Future directions for thrombophilia testing - Prospective clinical studies to define:
- Role, if any, of screening asymptomatic family members or individuals in high-risk situations.
- Impact on optimal therapy for patients with venous thrombosis and thrombophilia.
- Better education for providers as well as consumers concerning risk factors, prevention strategies, need for genetic counseling, etc.
Return to Top
Return to Top
Return to Menu
|